Shares of Alexion Pharmaceuticals (ALXN) were climbing over 2.3% in mid-morning trading on Tuesday after the biopharmaceutical firm secured FDA approval for its Soliris, a treatment for adult patients with generalized myasthenia gravis (gMG).

The treatment is approved for patients with gMG who are anti-acetylcholine receptor (AchR) antibody-positive.

Myasthenia gravis is a chronic condition that causes muscles to tire and weaken easily.

In a Phase 3 REGAIN study, Soliris proved beneficial for patients with anti-AchR antibody-positive gMG who had previously "failed immunosuppressive treatment and continued to suffer from significant unresolved disease symptoms," Alexion said. These symptoms included difficulties with talking, walking, swallowing and breathing.

"Today's approval is a significant milestone for Alexion and, more importantly, for the subset of patients with anti-AchR antibody-positive gMG who continue to suffer from significant unresolved disease symptoms despite existing treatment options," said John Orloff, M.D., Executive VP and Head of Research & Development at Alexion. 

More of What's Trending on TheStreet:

More from Stocks

Oracle Taking a 'Holistic' Approach to the Cloud

Oracle Taking a 'Holistic' Approach to the Cloud

IBM Stock Jumps After 'Cleanest Quarter in Years'

IBM Stock Jumps After 'Cleanest Quarter in Years'

Market Movers: January FOMC Meeting

Market Movers: January FOMC Meeting

Ford Reports Mixed Q4 Financial Results as International Performance Falters

Ford Reports Mixed Q4 Financial Results as International Performance Falters

TD Ameritrade CEO Breaks Down Earnings and 2019 Outlook

TD Ameritrade CEO Breaks Down Earnings and 2019 Outlook